Skip to main content
Clinical Trials/NCT00594152
NCT00594152
Completed
Phase 3

Anti-Nephropathic Effects of Chronic Intermittent Intravenous Insulin Therapy (CIIIT)

Joslin Diabetes Center1 site in 1 country71 target enrollmentJanuary 1993

Overview

Phase
Phase 3
Intervention
CIIIT
Conditions
Diabetic Nephropathy
Sponsor
Joslin Diabetes Center
Enrollment
71
Locations
1
Primary Endpoint
Rate of loss of creatinine clearance
Status
Completed
Last Updated
18 years ago

Overview

Brief Summary

Investigators with the goal of optimizing glycemic and blood pressure control saw type 1 diabetic patients weekly. A control group received 3-4 subcutaneous insulin injections per day; an intravenous insulin pulsed infusion group received, in addition, three one hour infusions in a pulsatile fashion over one eight hour period each week. Patients were followed for 12 months with periodic testing of renal function by repeated blood and urinary analyses; diabetes control by blood testing and diabetes impact measurement score; cardiac and autonomic function by echocardiography, 24 hour electrocardiographic testing; and visual changes with repeated fundus photography. The study hypothesis was that correction of respiratory quotient would correct the defect leading to microvascular complications of diabetes (Type 1).

Registry
clinicaltrials.gov
Start Date
January 1993
End Date
January 1995
Last Updated
18 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Type 1 diabetics with proteinuria willing to be seen weekly for the evaluation of renal function

Exclusion Criteria

  • Associated active medical diseases that would not permit evaluation of stable renal disease over 18 months

Arms & Interventions

Treatment

Intervention: three one-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to standard subcutaneous insulin.

Intervention: CIIIT

Outcomes

Primary Outcomes

Rate of loss of creatinine clearance

Time Frame: 18 months

Secondary Outcomes

  • Quality of life assessment(12 to 18 months)
  • Change in cardiac autonomic function(12 to18 months)
  • Change in retinal photos(12 to 18 months)
  • Change in cardiac function(12 to 18 months)

Study Sites (1)

Loading locations...

Similar Trials